Fenofibrate inhibits intestinal Cl- secretion by blocking basolateral KCNQ1 K+ channels.
Fibrates are peroxisome proliferator-activated receptor-alpha (PPARalpha) ligands in widespread clinical use to lower plasma triglyceride levels. We investigated the effect of fenofibrate and clofibrate on ion transport in mouse intestine and in human T84 colonic adenocarcinoma cells through the use of short-circuit current (I(sc)) and ion flux analysis. In mice, oral administration of fenofibrate produced a persistent inhibition of cAMP-stimulated electrogenic Cl(-) secretion by isolated jejunum and colon without affecting electroneutral fluxes of (22)Na(+) or (86)Rb(+) (K(+)) across unstimulated colonic mucosa. When applied acutely to isolated mouse intestinal mucosa, 100 microM fenofibrate inhibited cAMP-stimulated I(sc) within 5 min. In T84 cells, fenofibrate rapidly inhibited approximately 80% the Cl(-) secretory responses to forskolin (cAMP) and to heat stable enterotoxin STa (cGMP) without affecting the response to carbachol (Ca(2+)). Both fenofibrate and clofibrate inhibited cAMP-stimulated I(sc) with an IC(50) approximately 1 muM, whereas other PPARalpha activators (gemfibrozil and Wy-14,643) were without effect. Membrane permeabilization experiments on T84 cells indicated that fenofibrate inhibits basolateral cAMP-stimulated K(+) channels (putatively KCNQ1/KCNE3) without affecting Ca(2+)-stimulated K(+) channel activity, whereas clofibrate inhibits both K(+) pathways. Fenofibrate had no effect on apical cAMP-stimulated Cl(-) channel activity. Patch-clamp analysis of HEK-293T cells confirmed that 100 microM fenofibrate rapidly inhibits K(+) currents associated with ectopic expression of human KCNQ1 with or without the KCNE3 beta-subunit. We conclude that fenofibrate inhibits intestinal cAMP-stimulated Cl(-) secretion through a nongenomic mechanism that involves a selective inhibition of basolateral KCNQ1/KCNE3 channel complexes. Our findings raise the prospect of fenofibrate as a safe and effective antidiarrheal agent.
Bajwa
Poonam J
PJ
Division of Biomedical Sciences, University of California, Riverside, CA 92521-0121, USA.
Alioua
Abderrahmane
A
Lee
Jimmy W
JW
Straus
Daniel S
DS
Toro
Ligia
L
Lytle
Christian
C
D002121:Calcium Channel Blockers / Q000008:administration & dosage; D002460:Cell Line; D002713:Chlorine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D011345:Fenofibrate / Q000008:administration & dosage*; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D007413:Intestinal Mucosa / Q000187:drug effects / Q000502:physiology*; D015640:Ion Channel Gating / Q000187:drug effects / Q000502:physiology*; D051657:KCNQ1 Potassium Channel / Q000037:antagonists & inhibitors / Q000502:physiology*
D002121:Calcium Channel Blockers; D000960:Hypolipidemic Agents; D051657:KCNQ1 Potassium Channel; C496909:KCNQ1 protein, human; D002713:Chlorine; D011345:Fenofibrate